PDCI is pleased to inform you of the launch of its podcast series, Between the Lines. Between the Lines invites thought leaders and industry experts to share their insights about the trends and controversies that are shaping the pharmaceutical policy landscape in Canada today.
The first episode focuses on the impact the Patented Medicine Prices Review Board (PMPRB) drug pricing reforms will have on Canadian stakeholders.
Kimberly Robinson, Director of Pricing and Market Access at PDCI, shares her perspective on why lower patented drug prices are problematic. Prior to joining PDCI, Kimberly was the founder and Principal Consultant at PharmaKare. She also spent 18 years at Janssen where she gained expertise in all aspects of market access, including HTA strategy development, health economics and outcomes research, government and stakeholder relations, and strategic pricing.
Please join our host Brittany Humphries, a Health Economic Modeler & Policy Research Associate at PDCI, as we read Between the Lines of this critically important policy discussion.
We hope you enjoy this episode and will stay tuned for our upcoming episodes discussing the future of pharmacare, the changing private payer landscape and more!
Listen to the first episode here.
For more information, comments or inquiries, please reach out to Julia Shen from PDCI Market Access.